The novel compound NO-1886 elevates plasma high-density lipoprotein cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase without any effect on cholesteryl ester transfer protein activity
- 31 March 1997
- journal article
- research article
- Published by Elsevier in Metabolism
- Vol. 46 (3) , 257-260
- https://doi.org/10.1016/s0026-0495(97)90250-x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic ratsDiabetes, 1995
- Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol.Journal of Clinical Investigation, 1994
- The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis.Journal of Clinical Investigation, 1993
- High-Density Lipoprotein — The Clinical Implications of Recent StudiesNew England Journal of Medicine, 1989
- Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activityAtherosclerosis, 1988
- Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemiaAtherosclerosis, 1985
- High density lipoprotein metabolism.Journal of Lipid Research, 1984
- A selective decline of postheparin plasma hepatic triglyceride lipase in hypothyroid ratsMetabolism, 1980